Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puretech Health Plc ADR (NQ: PRTC )

22.36 -0.19 (-0.84%)
Streaming Delayed Price Updated: 11:09 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puretech Health Plc ADR

< Previous 1 2 3 4 5 6 7 8 Next >
PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I
From PureTech Health
Via Business Wire
PureTech to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From PureTech Health
Via Business Wire
PureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting Norms
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-... 
Via Benzinga
Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today
PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special... 
Via Benzinga
PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar
From PureTech Health plc
Via Business Wire
PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee
From PureTech Health plc
Via Business Wire
PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities
From PureTech Health
Via Business Wire
PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions
From PureTech Health plc
Via Business Wire
PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Biofrontera (NASDAQ:BFRI) shares ... 
Via Benzinga
PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro
From PureTech Health plc
Via Business Wire
PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates
From PureTech Health plc
Via Business Wire
PureTech Announces Participation in Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
From PureTech Health plc
Via Business Wire
PureTech Announces Participation at the Jefferies London Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Is Pleased to Note Publication in Nature’s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan
From PureTech Health plc
Via Business Wire
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance
From PureTech Health plc
Via Business Wire
PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From PureTech Health plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.